# miR-548ac and miR-378j as Potential Diagnostic Biomarkers in Gastric Cancer: A Case-Control Study

**Authors:** Seyed Mahdi Mousavi, Sogand Vahidi, Seyedeh Elham Norollahi, Kosar Babaei, Ebrahim Mirzajani, Pirouz Samidoust, Zivar Salehi, Ali Akbar Samadani

PMC · DOI: 10.34172/mejdd.2025.434 · Middle East Journal of Digestive Diseases · 2025-07-30

## TL;DR

This study explores miR-548ac and miR-378j as potential biomarkers for diagnosing gastric cancer, finding that miR-548ac is significantly upregulated in cancerous tissues.

## Contribution

The study identifies miR-548ac as a novel potential diagnostic biomarker for gastric cancer.

## Key findings

- miR-548ac is significantly upregulated in gastric cancer tissues compared to normal tissues.
- miR-378j shows no significant difference in expression between tumor and normal tissues.

## Abstract

Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide. Despite improvements in diagnostic techniques, GC is often diagnosed at advanced stages. MicroRNAs (miRNAs) have become recognized as important regulators in cancer development, influencing processes such as cell proliferation, migration, invasion, and apoptosis. This study examined the expression levels of two microRNAs, miR-548ac and miR-378j, in GC tissue.

Tumor and margin tissues were collected from 20 patients diagnosed with gastric adenocarcinoma, and control tissue samples were obtained from 20 healthy individuals. Total RNA was extracted, and cDNA synthesis was performed. Quantitative real-time polymerase chain reaction (qPCR) was used to assess the expression levels of miR-548ac and miR-378j, with miR-16 as the internal control. Statistical analysis was performed using REST software, with SPSS software used for further clinical correlation analysis.

The expression of miR-548ac was significantly upregulated in gastric tumor tissues compared with margin tissues and healthy samples (P=0.002). miR-378j expression, on the other hand, showed no significant difference between tumor and normal tissues (P=0.05). Statistical analysis revealed a borderline significant association between miR-548ac expression and tumor stage and grade, but found no significant correlation with lymph node or distant metastasis. Additionally, the miR-378j expression did not show significant correlations with any clinicopathological features.

miR-548ac is significantly upregulated in GC tissues and may serve as a potential biomarker for GC diagnosis and prognosis, particularly in more advanced stages. In contrast, miR-378j does not appear to have a strong association with GC and may not be helpful as a diagnostic marker.

## Linked entities

- **Diseases:** gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** FRAT2 (FRAT regulator of Wnt signaling pathway 2) [NCBI Gene 23401] {aka FRAT-2}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, MIR378J (microRNA 378j) [NCBI Gene 102465136] {aka hsa-mir-378j}, MIR378A (microRNA 378a) [NCBI Gene 494327] {aka MIR378, MIRN378, hsa-mir-378, hsa-mir-378a, miRNA378}, MIR148A (microRNA 148a) [NCBI Gene 406940] {aka MIRN148, MIRN148A, hsa-mir-148, mir-148a}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, WNT2 (Wnt family member 2) [NCBI Gene 7472] {aka INT1L1, IRP}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, MIR940 (microRNA 940) [NCBI Gene 100126328] {aka MIRN940, hsa-mir-940, mir-940}, MIR17 (microRNA 17) [NCBI Gene 406952] {aka MIR17-5p, MIR91, MIRN17, MIRN91, hsa-mir-17, miR-17}, MIR145 (microRNA 145) [NCBI Gene 406937] {aka MIRN145, miR-145, miRNA145}, GDE1 (glycerophosphodiester phosphodiesterase 1) [NCBI Gene 51573] {aka 363E6.2, MIR16}, TMEM158 (transmembrane protein 158) [NCBI Gene 25907] {aka BBP, RIS1, p40BBP}, RXRA (retinoid X receptor alpha) [NCBI Gene 6256] {aka NR2B1, RXR-alpha, RXRalpha}, MIR1207 (microRNA 1207) [NCBI Gene 100302175] {aka MIRN1207, hsa-mir-1207}, MIR146A (microRNA 146a) [NCBI Gene 406938] {aka MIRN146, MIRN146A, miR-146a, miRNA146A}, MIR1182 (microRNA 1182) [NCBI Gene 100302132] {aka MIRN1182, hsa-mir-1182}, MIR548AC (microRNA 548ac) [NCBI Gene 100616384], WNT2B (Wnt family member 2B) [NCBI Gene 7482] {aka WNT13}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MIR1260B (microRNA 1260b) [NCBI Gene 100422991] {aka mir-1260b}, MIR216A (microRNA 216a) [NCBI Gene 406998] {aka MIR216, MIRN216, MIRN216A, miRNA216, mir-216, mir-216a}, MIR133B (microRNA 133b) [NCBI Gene 442890] {aka MIRN133B, miRNA133B, mir-133b}, GRK5 (G protein-coupled receptor kinase 5) [NCBI Gene 2869] {aka FP2025, GPRK5}, MIR20A (microRNA 20a) [NCBI Gene 406982] {aka C13orf25, MIR20, MIRH1, MIRHG1, MIRN20, MIRN20A}, SMAD2 (SMAD family member 2) [NCBI Gene 4087] {aka CHTD8, JV18, JV18-1, LDS6, MADH2, MADR2}, E2F3 (E2F transcription factor 3) [NCBI Gene 1871] {aka E2F-3}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, TCF4 (transcription factor 4) [NCBI Gene 6925] {aka CDG2T, E2-2, FCD2, FECD3, ITF-2, ITF2}, LEF1 (lymphoid enhancer binding factor 1) [NCBI Gene 51176] {aka ECTD1, ECTD17, LEF-1, TCF10, TCF1ALPHA, TCF7L3}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, WNT10B (Wnt family member 10B) [NCBI Gene 7480] {aka SHFM6, STHAG8, WNT-12}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, SDAD1 (SDA1 domain containing 1) [NCBI Gene 55153] {aka Sda1}, MIR506 (microRNA 506) [NCBI Gene 574511] {aka MIRN506, hsa-mir-506, mir-506}, VIM (vimentin) [NCBI Gene 7431], CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, MIR411 (microRNA 411) [NCBI Gene 693121] {aka MIRN411, hsa-mir-411, mir-411}, SOS2 (SOS Ras/Rho guanine nucleotide exchange factor 2) [NCBI Gene 6655] {aka NS9, SOS-2}
- **Diseases:** lymph node metastasis (MESH:D008207), Gastric Cancer (MESH:D013274), obesity (MESH:D009765), breast cancer (MESH:D001943), gastric tumorigenesis (MESH:D063646), fungal infections (MESH:D009181), hepatocellular carcinoma (MESH:D006528), multiple sclerosis (MESH:D009103), laryngeal cancer (MESH:D007822), kidney cancer (MESH:D007680), glioma (MESH:D005910), distant metastasis (MESH:D009362), node (MESH:D012804), Helicobacter pylori infection (MESH:D016481), adolescent idiopathic scoliosis (OMIM:181800), colon cancer (MESH:D015179), lung cancer (MESH:D008175), gastrointestinal disorders (MESH:D005767), cancer (MESH:D009369), liver fibrosis (MESH:D008103)
- **Chemicals:** phenol (MESH:D019800), water (MESH:D014867), chloroform (MESH:D002725), agarose (MESH:D012685), Isopropanol (MESH:D019840), ethanol (MESH:D000431), RNSol H (-), DEPC (MESH:D004047), salt (MESH:D012492), nitrogen (MESH:D009584)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12958308/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12958308/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12958308/full.md

---
Source: https://tomesphere.com/paper/PMC12958308